Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10 avr. 2018 08h01 HE
|
Achaogen, Inc.
-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif.,...
Achaogen Announces New Employment Inducement Grants
22 mars 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin
21 mars 2018 08h00 HE
|
Achaogen, Inc.
-- Meeting planned for May 2, 2018 -- SOUTH SAN FRANCISCO, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative...
Achaogen to Present at Needham & Company’s 17th Annual Healthcare Conference
14 mars 2018 08h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for March 27, 2018 -- SOUTH SAN FRANCISCO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company...
Achaogen to Present at the Cowen and Company 38th Annual Health Care Conference
06 mars 2018 08h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for March 13, 2018 -- SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company...
Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
27 févr. 2018 16h01 HE
|
Achaogen, Inc.
-- Plazomicin New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA);June 25, 2018 set as PDUFA action date -- -- Orally-administered antibacterial candidate C-Scape achieved...
Achaogen Announces New Employment Inducement Grants
21 févr. 2018 16h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018
13 févr. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Achaogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
07 févr. 2018 08h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for February 15, 2018 at 9:30 a.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage...
Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer
30 janv. 2018 10h07 HE
|
Achaogen, Inc.
-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI) -- -- VAI status provides a clear regulatory path for potential approval of plazomicin out of McPherson...